Drug Trial Radar · NCT07217301
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Nov 26, 2025
Primary completion
Nov 1, 2028
Study completion Dec 1, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Innovent Biologics (Suzhou) Co. Ltd.
- First posted
- Oct 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. NSCLC can be divided into types based on where cancer starts. Some NSCLC starts in the cells that line the larger airways near the center of the lungs. This is called squamous NSCLC. Other NSCLC often starts in the outer parts of the lungs, in cells that make mucus. This is called nonsquamous NSCLC. This study focuses on squamous and nonsquamous NSCLC in later stages (advanced). This means that the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery (unresectable). People with unresectable, advanced or metastatic squamous or nonsquamous NSCLC often get treatment with immunotherapy and/or platinum-based chemotherapy (such as cisplatin or carboplatin). Immunotherapy helps the body's germ-fighting (immune) system fight cancer. Chemotherapy kills cancer cells or slows their growth. Over time, these treatments may stop working and the cancer can get worse. Researchers are looking for ways to make immunotherapy work better. One approach is to help the immune system recognize cancer more easily by activating certain cells, called T cells, to attack and kill the tumor cells. TAK-928 is designed to attach to T cells in the tumor. This may make the T-cells more active and increase their number. This may help the body fight the cancer and destroy tumor cells. The main aim of this study is to learn how well TAK-928 works and compares with the usual treatment (also called standard of care), docetaxel, in adults with unresectable, advanced or metastatic squamous or nonsquamous NSCLC. Another aim is to learn how safe TAK-928 is in adults with NSCLC. The participants can be treated for up to 2 years (24 months). Total treatment duration can vary depending on how a participant responds, side effects, or other reasons. Researchers will check a participant's condition until the treatment is ended. During the study, participants will visit the study clinic several times.
Conditions
- IO Resistant Squamous and Nonsquamous NSCLC
Interventions
TAK-928Drug
TAK-928 will be administered by IV infusion.
Control ArmDrug
Comparator product will be administered by IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Squamous NSCLC Part: Confirmed Objective Response Rate (cORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1Time frame: Up to 26 months
- Squamous and Nonsquamous NSCLC Part: Overall Survival (OS)Time frame: Up to 26 months
- SRI Part: Percentage of Participants with Dose-limiting Toxicities (DLTs)Time frame: Up to 28 days after first dose (Day 1)
- SRI Part: Percentage of Participants With Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Immune-Related Adverse Events (irAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation and DeathsTime frame: From screening up to 26 months
Locations
50 sites in 3 countries. Site status is shown where the registry gives one.
St. Bernards Healthcare
Jonesboro, Arkansas · Recruiting
Apex Research
Fair Oaks, California · Recruiting
Memorial Care
Fountain Valley, California · Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
Translation Research in Oncology- US, INC (TRIO-US)
Torrance, California · Recruiting
MedStar Georgetown Cancer Institute-Oncology Research
Washington D.C., District of Columbia · Recruiting
D & H Cancer Research Center
Margate, Florida · Recruiting
BRCR Global
Tamarac, Florida · Recruiting
Oncology Hematology Associates
Springfield, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Recruiting
The University of Texas M.D Anderson Cancer Center (MDACC)
Houston, Texas · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
The Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
The Fourth Hospital of Hebei University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Withdrawn
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
The First Affiliated Hospital of Xi'An Jiaotong University
Xi'an, Shannxi, China · Recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.